Gapping up
In reaction to earnings/guidance:
- MNDY +15.4%, PROC +3.2%, TSEM +2.4%, AI +2.2%, BHVN +0.8%, BOC +0.7%
Other news:
- NGMS +119.3% (to be acquired by Aristocrat for $29.50 per share in cash)
- SRPT +28.7% (receives Positive Vote from FDA Advisory Committee Meeting for SRP-9001 gene therapy to treat duchenne muscular dystrophy)
- MMP +14.1% (Magellan Midstream to be acquired by ONEOK (OKE) for implied value of $67.50 per unit)
- SD +10.2% (announces one-time $2.00 per share dividend, a $75 million stock repurchase program, and an on-going planned quarterly dividend of $0.10 per share planned to commence in August 2023)
- QURE +7.4% (entered into a definitive agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of HEMGENIX to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400 mln in cash)
- ALTI +6.7% (to delay 10-Q filing)
- MNOV +1.9% (receives a notice of intention to grant for a new patent covering MN-166 (ibudilast) for patients with microorganism infection in Europe)
- BTI +1.4% (appoints Tadeu Marroco as CEO)
- NEM +0.8% (acquires Newcrest)
- LRMR +0.8% (announces preliminary top-line data from the 25 mg cohort of its Phase 2, four-week, placebo-controlled, dose exploration trial of CTI-1601 in participants with Friedreich's ataxia) .
Analyst comments:
- AGS +6.8% (upgraded to Buy from Hold at Jefferies)
- NVRO +3.7% (upgraded to Outperform from Perform at Oppenheimer)
- ALB +2.6% (upgraded to Outperform from Neutral at Robert Baird)
- BWA +1.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- META +1.2% (upgraded to Buy from Hold at Loop Capital)